Bangkok Genomics Innovation PCL (BKK:BKGI)

Market Cap	948.00M
Revenue (ttm)	331.82M
Net Income (ttm)	39.13M
Shares Out	600.00M
EPS (ttm)	0.07
PE Ratio	24.24
Forward PE	35.11
Dividend	0.05 (3.05%)
Ex-Dividend Date	May 6, 2025

Volume	995,413
Average Volume	589,341
Open	1.630
Previous Close	1.640
Day's Range	1.580 - 1.670
52-Week Range	1.110 - 3.220
Beta	n/a
RSI	51.96
Earnings Date	Nov 6, 2025

About BKK:BKGI

Bangkok Genomics Innovation Public Company Limited provides medical analysis services in Thailand. The company offers screening for fetal chromosomal abnormalities using non-invasive prenatal testing under the NIFTY brand; preimplantation chromosomal abnormality and thalassemia carrier gene screening; infectious disease group analysis; testing for human papilloma virus; and monkeypox virus, COVID-19 Pathogen, and COVID-19 pathogen immunity testing. It also provides other screening tests, such as cancer-related gene screening to predict the risk...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2017
• Country: Thailand
• Stock Exchange: Stock Exchange of Thailand
• Ticker Symbol: BKGI

Financial Performance

In 2024, BKK:BKGI's revenue was 337.59 million, an increase of 37.57% compared to the previous year's 245.39 million. Earnings were 50.17 million, an increase of 56.09%.